MA50546A - Compositions et méthodes pour l'internalisation d'enzymes - Google Patents
Compositions et méthodes pour l'internalisation d'enzymesInfo
- Publication number
- MA50546A MA50546A MA050546A MA50546A MA50546A MA 50546 A MA50546 A MA 50546A MA 050546 A MA050546 A MA 050546A MA 50546 A MA50546 A MA 50546A MA 50546 A MA50546 A MA 50546A
- Authority
- MA
- Morocco
- Prior art keywords
- internalization
- enzymes
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
- C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762516656P | 2017-06-07 | 2017-06-07 | |
US201762574719P | 2017-10-19 | 2017-10-19 | |
US201862673098P | 2018-05-17 | 2018-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50546A true MA50546A (fr) | 2020-09-16 |
Family
ID=62815133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050546A MA50546A (fr) | 2017-06-07 | 2018-06-06 | Compositions et méthodes pour l'internalisation d'enzymes |
Country Status (16)
Country | Link |
---|---|
US (2) | US11208458B2 (fr) |
EP (1) | EP3635009A1 (fr) |
JP (2) | JP7348844B2 (fr) |
KR (1) | KR20200015932A (fr) |
CN (1) | CN110809583A (fr) |
AU (1) | AU2018281280A1 (fr) |
BR (1) | BR112019025888A2 (fr) |
CA (1) | CA3066569A1 (fr) |
CL (1) | CL2019003586A1 (fr) |
CO (1) | CO2019014682A2 (fr) |
IL (1) | IL271193A (fr) |
MA (1) | MA50546A (fr) |
NZ (1) | NZ760232A (fr) |
PH (1) | PH12019550261A1 (fr) |
TW (2) | TW202405021A (fr) |
WO (1) | WO2018226861A1 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140135233A (ko) | 2012-03-14 | 2014-11-25 | 리제너론 파마슈티칼스 인코포레이티드 | 다중특이성 항원-결합 분자 및 그것의 용도 |
ES2833937T3 (es) * | 2015-12-08 | 2021-06-16 | Regeneron Pharma | Composiciones y métodos para internalizar enzimas |
WO2018226861A1 (fr) * | 2017-06-07 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes pour l'internalisation d'enzymes |
MX2020008274A (es) * | 2018-02-07 | 2020-11-11 | Regeneron Pharma | Metodos y composiciones para la administracion de proteinas terapeuticas. |
US20210079109A1 (en) * | 2018-05-17 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
JP2021533200A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
WO2020106814A1 (fr) | 2018-11-21 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-staphylococcus et leurs utilisations |
CN113301925A (zh) | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | 用于溶酶体靶向的双官能分子以及相关的组合物和方法 |
JP2022553830A (ja) * | 2019-11-05 | 2022-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | N末端scFv多重特異性結合分子 |
WO2022087484A1 (fr) * | 2020-10-23 | 2022-04-28 | Williams Katherine L | Anticorps contre le coronavirus sars-cov-2 |
KR102494508B1 (ko) * | 2020-12-23 | 2023-02-06 | 아주대학교산학협력단 | CRISPR/Cas 시스템을 이용한 유도만능 줄기세포 제조방법 |
IL305318A (en) * | 2021-02-19 | 2023-10-01 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
WO2023016828A2 (fr) * | 2021-07-30 | 2023-02-16 | Vib Vzw | Liants du récepteur mannose-6-phosphate indépendants des cations pour la dégradation ciblée de protéines |
TW202332767A (zh) | 2022-02-02 | 2023-08-16 | 美商雷傑納榮製藥公司 | 用於治療龐貝氏症之抗TfR:GAA及抗CD63:GAA插入 |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
CN114731987B (zh) * | 2022-05-19 | 2023-06-23 | 华芯微鱼(苏州)生物科技有限公司 | 颅缝早闭症小鼠模型、其构建方法及应用 |
WO2024026488A2 (fr) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant un locus de récepteur de transférrine modifié |
WO2024035955A2 (fr) * | 2022-08-12 | 2024-02-15 | Lycia Therapeutics, Inc. | Anticorps bispécifiques et constructions pour dégradation de ciblage lysosomal et leurs procédés d'utilisation |
WO2024098002A1 (fr) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Protéines de liaison de sous-unité auxiliaire gamma 1 du canal calcique dépendant de la tension (cacng1) et administration médiée par cacng1 au muscle squelettique |
WO2024107765A2 (fr) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions et procédés d'administration médiée par le récepteur 3 du facteur de croissance des fibroblastes à des astrocytes |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US5156965A (en) | 1983-11-29 | 1992-10-20 | Igen, Inc. | Catalytic antibodies |
US5229272A (en) | 1989-04-25 | 1993-07-20 | Igen, Inc. | Catalytic antibody components |
WO1994025573A1 (fr) | 1993-04-23 | 1994-11-10 | Igen, Inc. | Anticorps catalytiques hydrolysant des amides primaires et procedes permettant d'obtenir ces anticorps |
US5126258A (en) | 1984-09-07 | 1992-06-30 | Scripps Clinic And Research Foundation | Molecules with antibody combining sites that exhibit catalytic properties |
US5030717A (en) | 1986-09-17 | 1991-07-09 | Scripps Clinic And Research Foundation | Antibodies which catalyze hydrolysis of ester bonds |
US5602021A (en) | 1994-12-29 | 1997-02-11 | Catalytic Antibodies, Inc. | Method for generating proteolytic enzymes specific against a selected peptide sequence |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0840797B1 (fr) | 1995-07-25 | 2014-09-03 | Crucell Holland B.V. | Procedes et moyens d'apport cible de genes |
US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
US5858351A (en) | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
US5962313A (en) | 1996-01-18 | 1999-10-05 | Avigen, Inc. | Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme |
DK0932417T3 (da) | 1996-10-17 | 2003-04-14 | Immunomedics Inc | Non-antigent toxinkonjugat og fusionsprotein af internaliserende receptorsystem |
CN1259875A (zh) | 1997-06-11 | 2000-07-12 | 伦敦大学药学院 | 含有与前体药物结合的抗体-酶偶联物的药物组合物 |
IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
US6703488B1 (en) | 1998-01-15 | 2004-03-09 | Center For Molecular Medicine And Immunology | Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
US6855804B2 (en) | 1998-03-23 | 2005-02-15 | Board Of Regents, The University Of Texas System | Covalently reactive transition state analogs and methods of use thereof |
ES2396693T3 (es) | 1998-04-02 | 2013-02-25 | Xintela Ab | Heterodímero de integrina y subunidad del mismo |
WO2000022110A2 (fr) | 1998-10-09 | 2000-04-20 | President And Fellows Of Harvard College | Proteolyse ciblee par recrutement de ligases proteiniques d'ubiquitine |
US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
EP1322750A4 (fr) | 2000-09-08 | 2004-09-29 | California Inst Of Techn | Medicament chimere de ciblage de proteolyse |
US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20060210474A1 (en) | 2000-11-29 | 2006-09-21 | Young David S | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7431923B2 (en) | 2005-01-03 | 2008-10-07 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7442777B2 (en) | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
ES2349235T3 (es) | 2001-12-21 | 2010-12-29 | Alcon, Inc. | Uso de nanopartículas inorgánicas sintéticas como vehículos para farmacos oftálmicos. |
JP2006506317A (ja) | 2002-01-11 | 2006-02-23 | バイオマリン ファーマシューティカル インコーポレイテッド | 治療用リソソーム酵素の送達のための酵素送達系としてのp97の使用 |
US7858367B2 (en) | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
EP1587923B1 (fr) | 2003-01-22 | 2011-08-24 | Duke University | Constructions ameliorees permettant d'exprimer des polypeptides lysosomiaux |
SE0301087D0 (sv) | 2003-04-14 | 2003-04-14 | Cartela Ab | New monoclonal antibody |
US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
WO2004098648A1 (fr) | 2003-05-01 | 2004-11-18 | Genzyme Corporation | Therapie genique pour troubles neurometaboliques |
WO2004113521A1 (fr) | 2003-06-18 | 2004-12-29 | Direvo Biotech Ag | Nouvelles entites biologiques et leur utilisation |
US7371539B2 (en) | 2003-12-03 | 2008-05-13 | President And Fellows Of Harvard College | Targeted polypeptide degradation |
WO2005077093A2 (fr) | 2004-02-06 | 2005-08-25 | Biomarin Pharmaceutical Inc. | Fabrication d'enzymes lysosomales hautement phosphorylees et utilisations associees |
US20050244400A1 (en) | 2004-02-10 | 2005-11-03 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
US20060078542A1 (en) | 2004-02-10 | 2006-04-13 | Mah Cathryn S | Gel-based delivery of recombinant adeno-associated virus vectors |
US20060171926A1 (en) | 2004-04-30 | 2006-08-03 | Passini Marco A | Gene therapy for neurometabolic disorders |
WO2006066066A2 (fr) | 2004-12-15 | 2006-06-22 | University Of North Carolina At Chapel Hill | Vecteurs chimeriques |
JP5137814B2 (ja) | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート |
PL3058959T3 (pl) | 2005-05-02 | 2019-07-31 | Genzyme Corporation | Terapia genowa dla zaburzeń neurometabolicznych |
MX2007016039A (es) | 2005-06-17 | 2008-10-27 | Univ North Carolina | Metodos, sistemas y materiales de fabricacion de nanoparticulas. |
ES2735531T3 (es) | 2005-08-23 | 2019-12-19 | Univ Pennsylvania | ARN que contiene nucleósidos modificados y métodos de uso del mismo |
DK2374818T3 (da) | 2006-06-02 | 2013-01-21 | Regeneron Pharma | Højaffinitetsantistoffer mod human IL-6-receptor |
US20080089891A1 (en) | 2006-07-26 | 2008-04-17 | Arius Research, Inc. | Cancerous disease modifying antibodies |
CA2669347A1 (fr) | 2006-11-13 | 2008-05-29 | Zystor Therapeutics, Inc. | Methodes de traitement de la maladie de pompe |
US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
US20100221225A1 (en) | 2007-02-23 | 2010-09-02 | University Of Florida Research Foundation, Inc | Compositions and methods for treating glycogen storage diseases |
WO2009075815A1 (fr) | 2007-12-07 | 2009-06-18 | Duke University | Thérapie génique d'immunomodulation |
WO2009094561A1 (fr) | 2008-01-24 | 2009-07-30 | The Government Of The United States Of America As Represented By The Secretary Of The Departmentof | Internalisation induite de récepteurs de surface |
US9617548B2 (en) * | 2008-04-22 | 2017-04-11 | Vib Vzw | Liver-specific nucleic acid regulatory elements and methods and use thereof |
HUE034850T2 (en) | 2008-05-07 | 2018-03-28 | Biomarin Pharm Inc | Lysosomal targeting peptides and their use |
EP2475376B1 (fr) | 2009-06-17 | 2016-03-30 | BioMarin Pharmaceutical Inc. | Formulations pour enzymes lysosomales |
KR20120027055A (ko) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
WO2011012316A2 (fr) | 2009-07-31 | 2011-02-03 | Ludwig-Maximilians-Universität | Arn ayant une combinaison de nucléotides non modifiés et modifiés pour l'expression protéique |
WO2011029823A1 (fr) | 2009-09-09 | 2011-03-17 | Novartis Ag | Anticorps monoclonal réactif avec cd63 lors de son expression à la surface de mastocytes dégranulés |
US9453241B2 (en) * | 2010-05-04 | 2016-09-27 | Wayne State University | AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
WO2011139379A2 (fr) | 2010-05-06 | 2011-11-10 | Duke University | Méthode de traitement de patients suivant une thérapie de remplacement de protéine, une thérapie de remplacement de gène ou d'autres modalités thérapeutiques |
US9347050B2 (en) | 2010-09-29 | 2016-05-24 | Oxyrane Uk Limited | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
US8679478B2 (en) | 2010-10-04 | 2014-03-25 | Duke University | Methods of lysosomal storage disease therapy |
WO2012051220A1 (fr) | 2010-10-11 | 2012-04-19 | Wichita State University | Système de délivrance de médicaments de nanoparticules magnétiques composites |
US9279007B2 (en) | 2010-11-22 | 2016-03-08 | Amicus Therapeutics, Inc. | Signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins |
RS59661B2 (sr) | 2011-02-25 | 2023-06-30 | Regeneron Pharma | Adam6 miševi |
EP2687597B1 (fr) | 2011-03-16 | 2018-12-26 | Amano Enzyme Inc. | Alpha-glucosidase modifiée et ses applications |
US20140212503A1 (en) | 2011-03-17 | 2014-07-31 | Hyukjin Lee | Delivery system |
US9849195B2 (en) | 2011-03-31 | 2017-12-26 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
BR112013026976A2 (pt) | 2011-04-22 | 2019-09-24 | Genzyme Corp | alfa glucosidade ácida modificada com processamento acelerado |
US20120283503A1 (en) | 2011-04-29 | 2012-11-08 | The Johns Hopkins University | Nanoparticle loaded stem cells and their use in mri guided hyperthermia |
DK2714752T3 (en) | 2011-05-27 | 2018-02-26 | Amicus Therapeutics Inc | PROCEDURES FOR THE CONNECTION OF TARGETING PEPTIDES TO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENT OF LYSOSOMAL DISPOSAL DISEASES |
CA2859408C (fr) | 2011-12-20 | 2020-06-16 | Regeneron Pharmaceuticals, Inc. | Souris a chaines legeres humanisees |
KR20140135233A (ko) * | 2012-03-14 | 2014-11-25 | 리제너론 파마슈티칼스 인코포레이티드 | 다중특이성 항원-결합 분자 및 그것의 용도 |
JP2015523998A (ja) | 2012-06-19 | 2015-08-20 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 疾患を治療するための組成物および方法 |
ES2613691T3 (es) | 2012-07-11 | 2017-05-25 | Sangamo Biosciences, Inc. | Métodos y composiciones para el tratamiento de enfermedades por almacenamiento lisosomal |
JP2016514096A (ja) | 2013-02-20 | 2016-05-19 | バレリオン セラピューティクス, エルエルシー | ポンぺ病の処置のための方法および組成物 |
CA2901969A1 (fr) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methodes et compositions pour le traitement de la maladie de forbes-cori |
KR20240093939A (ko) | 2013-05-15 | 2024-06-24 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달 |
WO2014185908A2 (fr) | 2013-05-15 | 2014-11-20 | The Translational Genomics Research Institute | Clones d'hybridomes, anticorps monoclonaux et procédés d'utilisation |
US9388243B2 (en) | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
RU2018128780A (ru) | 2013-07-26 | 2018-12-05 | Юниверсити Оф Айова Рисерч Фаундейшн | Способы и композиции для лечения болезней мозга |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
SG11201605906UA (en) | 2014-01-21 | 2016-08-30 | Univ Bruxelles | Muscle-specific nucleic acid regulatory elements and methods and use thereof |
WO2016044947A1 (fr) | 2014-09-26 | 2016-03-31 | Exerkine Corporation | Exosomes utiles pour traiter une maladie de stockage lysosomal |
EP3220958A1 (fr) | 2014-10-24 | 2017-09-27 | Shire Human Genetic Therapies, Inc. | Ciblage lysosomal d'enzymes et utilisations associées |
MA41022A (fr) | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
AU2016341428B2 (en) | 2015-10-23 | 2021-12-02 | University Of Iowa Research Foundation | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
ES2833937T3 (es) | 2015-12-08 | 2021-06-16 | Regeneron Pharma | Composiciones y métodos para internalizar enzimas |
KR20230041833A (ko) | 2015-12-30 | 2023-03-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
MA46419A (fr) | 2016-02-05 | 2018-12-12 | Genmab As | Molécule de liaison aux antigènes multispécifique présentant de meilleures caractéristiques d'internalisation |
US10512676B2 (en) | 2016-03-30 | 2019-12-24 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
EP3452101A2 (fr) | 2016-05-04 | 2019-03-13 | CureVac AG | Arn codant pour une protéine thérapeutique |
BR112019004785A2 (pt) | 2016-09-12 | 2019-06-04 | Genethon | variantes de alfa-glicosidase ácida e usos das mesmas |
EP3293259A1 (fr) | 2016-09-12 | 2018-03-14 | Genethon | Variants d'alpha-glucosidase acide et leurs utilisations |
EP3293203A1 (fr) | 2016-09-12 | 2018-03-14 | Genethon | Variants d'alpha-glucosidase acide et leurs utilisations |
CN110198712A (zh) | 2016-11-04 | 2019-09-03 | 费城儿童医院 | 用于治疗神经退行性疾病的基因转移组合物、方法和用途 |
BR112019009316A2 (pt) | 2016-12-26 | 2019-08-06 | Japan Chem Res | anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie. |
SG11201904535VA (en) | 2017-01-27 | 2019-08-27 | Xintela Ab | Prevention and treatment of bone and cartilage damage or disease |
US20210393747A1 (en) | 2017-05-15 | 2021-12-23 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase |
WO2018226861A1 (fr) * | 2017-06-07 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes pour l'internalisation d'enzymes |
KR20220070075A (ko) | 2017-09-20 | 2022-05-27 | 4디 몰레큘러 테라퓨틱스 아이엔씨. | 아데노-관련 바이러스 변이체 캡시드 및 그 용도 |
EP3749756A4 (fr) | 2018-02-05 | 2021-12-08 | Audentes Therapeutics, Inc. | Éléments de régulation de la transcription et utilisations associées |
EA202091816A1 (ru) | 2018-02-05 | 2020-10-26 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Способ доставки лекарственного средства в мышцу |
MX2020008274A (es) | 2018-02-07 | 2020-11-11 | Regeneron Pharma | Metodos y composiciones para la administracion de proteinas terapeuticas. |
WO2019222411A1 (fr) | 2018-05-16 | 2019-11-21 | Spark Therapeutics, Inc. | Cassettes d'expression d'alpha-glucosidase acide optimisées par des codons et leurs méthodes d'utilisation |
WO2020028841A1 (fr) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Complexes de ciblage musculaire et leurs utilisations pour le traitement de la maladie de pompe |
US20220054656A1 (en) | 2018-11-16 | 2022-02-24 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus for treating pompe disease |
BR112021009913A2 (pt) | 2018-12-05 | 2021-08-17 | Abeona Therapeutics, Inc. | vetor viral adeno-associado recombinante para inserção gênica |
-
2018
- 2018-06-06 WO PCT/US2018/036306 patent/WO2018226861A1/fr active Application Filing
- 2018-06-06 CA CA3066569A patent/CA3066569A1/fr active Pending
- 2018-06-06 KR KR1020207000160A patent/KR20200015932A/ko not_active Application Discontinuation
- 2018-06-06 MA MA050546A patent/MA50546A/fr unknown
- 2018-06-06 CN CN201880037686.8A patent/CN110809583A/zh active Pending
- 2018-06-06 NZ NZ760232A patent/NZ760232A/en unknown
- 2018-06-06 AU AU2018281280A patent/AU2018281280A1/en active Pending
- 2018-06-06 US US16/001,717 patent/US11208458B2/en active Active
- 2018-06-06 JP JP2019567722A patent/JP7348844B2/ja active Active
- 2018-06-06 BR BR112019025888-4A patent/BR112019025888A2/pt unknown
- 2018-06-06 EP EP18737065.5A patent/EP3635009A1/fr active Pending
- 2018-06-07 TW TW112136735A patent/TW202405021A/zh unknown
- 2018-06-07 TW TW107119652A patent/TWI820027B/zh active
-
2019
- 2019-12-03 PH PH12019550261A patent/PH12019550261A1/en unknown
- 2019-12-05 IL IL271193A patent/IL271193A/en unknown
- 2019-12-06 CL CL2019003586A patent/CL2019003586A1/es unknown
- 2019-12-24 CO CONC2019/0014682A patent/CO2019014682A2/es unknown
-
2021
- 2021-11-17 US US17/528,828 patent/US20220195011A1/en active Pending
-
2022
- 2022-06-30 JP JP2022106089A patent/JP2022121630A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220195011A1 (en) | 2022-06-23 |
BR112019025888A2 (pt) | 2020-06-30 |
CA3066569A1 (fr) | 2018-12-13 |
JP2020523321A (ja) | 2020-08-06 |
US20180355017A1 (en) | 2018-12-13 |
NZ760232A (en) | 2023-05-26 |
AU2018281280A1 (en) | 2020-01-16 |
WO2018226861A4 (fr) | 2019-01-24 |
CO2019014682A2 (es) | 2020-01-17 |
KR20200015932A (ko) | 2020-02-13 |
JP7348844B2 (ja) | 2023-09-21 |
TW202405021A (zh) | 2024-02-01 |
EP3635009A1 (fr) | 2020-04-15 |
CN110809583A (zh) | 2020-02-18 |
WO2018226861A1 (fr) | 2018-12-13 |
CL2019003586A1 (es) | 2020-06-05 |
IL271193A (en) | 2020-01-30 |
RU2019143567A3 (fr) | 2022-02-15 |
RU2019143567A (ru) | 2021-07-09 |
US11208458B2 (en) | 2021-12-28 |
JP2022121630A (ja) | 2022-08-19 |
PH12019550261A1 (en) | 2020-07-13 |
TWI820027B (zh) | 2023-11-01 |
TW201920678A (zh) | 2019-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50546A (fr) | Compositions et méthodes pour l'internalisation d'enzymes | |
MA46643A (fr) | Méthodes et compositions pour le mappage d'arn | |
MA49403A (fr) | Compositions de pde5 et méthodes d'immunothérapie | |
MA50833A (fr) | Compositions et méthodes pour l'édition génique pour l'hémophilie a | |
IL278013A (en) | Modulators of secondary methyl enzymes, preparations and uses thereof | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
EP3471778A4 (fr) | Compositions et méthodes pour administrer des agents biomacromoléculaires | |
KR20180084895A (ko) | 효소 내재화 조성물 및 방법 | |
MA41028A (fr) | Méthodes et formulations pour le traitement de pathologies oculaires vasculaires | |
EP3386536A4 (fr) | Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation | |
MA43515A (fr) | Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll | |
MA49693A (fr) | Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue | |
MA49715A (fr) | Oligomères et conjugués d'oligomères | |
MA43378A (fr) | Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques | |
MA44391A (fr) | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 | |
MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
MA46842A (fr) | Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 | |
HK1254515A1 (zh) | 含有活動精子結構域的蛋白質2和癌症 | |
MA50354A (fr) | Anticorps ciblant le cd137 et leurs méthodes d'utilisation | |
MA43361A (fr) | Composition pour le soin et la protection de cultures | |
MX2017003121A (es) | Formulaciones de anticuerpos. | |
MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
IL272060A (en) | Compositions containing cannabinoids and methods of using them | |
MA44862A (fr) | Formulations de fulvestrant et méthodes d'utilisation de celles-ci | |
MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse |